---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-033020"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T10:49:18.976768+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nektar regains full rights to REZPEG from Lilly; plans Phase 2b in atopic dermatitis in 2023

## Summary
- Lilly terminated license agreement at will; termination effective July 22, 2023; Nektar gets all rights back.
- Nektar plans to initiate a Phase 2b study in moderate-to-severe atopic dermatitis in 2023 and explore other auto-immune indications.
- Phase 1b data showed dose-dependent improvement over placebo in EASI, EASI-75, vIGA-AD, and Itch NRS with durable response.
- Termination does not impact Nektar's cash guidance as milestone payments were not included in forecasts.
- CEO Howard Robin expresses confidence in REZPEG's potential as a remittive therapy for atopic dermatitis.

## SEC filing metadata
- accession: 0001213900-23-033020
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390023033020/0001213900-23-033020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390023033020/ea177525-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-033020
- JSON: https://secwatch.observer/filing/0001213900-23-033020.json
- Plain text: https://secwatch.observer/filing/0001213900-23-033020.txt

## Key facts
- Material Agreements
  NEKTAR THERAPEUTICS terminated License Agreement with Eli Lilly and Company valued at termination of all licenses and other rights granted by Nektar to Lilly with regard to the rezpegald (effective 2023-07-22).
  - Action: termination
  - Agreement: license
  - Counterparty: Eli Lilly and Company
  - Value: termination of all licenses and other rights granted by Nektar to Lilly with regard to the rezpegald
  - Effective: 2023-07-22
  source text: greement (the “Agreement”) with Eli Lilly and Company (“Lilly”), which Agreement was filed as an exhibit to Nektar’s Quarterly Report on Form 10-Q for the period ended September 30, 2017.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390023033020/0001213900-23-033020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.